Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Paraproteinemias 1Neoplasms, Plasma Cell 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia 1Colorectal Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Brain Neoplasms 1

Interventions

Bevacizumab 76Fluorouracil 56Cetuximab 47Leucovorin 44Oxaliplatin 43pembrolizumab 35Irinotecan 34Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 18trifluridine tipiracil drug combination 16Nivolumab 15Blood Specimen Collection 15Panitumumab 14regorafenib 13Magnetic Resonance Spectroscopy 13Trifluridine 12Standard of Care 12Gemcitabine 12Biopsy 12Cisplatin 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 9tislelizumab 8Trastuzumab 8Cyclophosphamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × Chromatin Immunoprecipitation Sequencing × Clear all
NCT07291414 2026-01-21

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

University of Michigan Rogel Cancer Center

Phase NA Recruiting
80 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡